156772-60-0

Basic information

• Product Name: 2,5-DIBROMO-3-FLUOROPYRIDINE
• Synonyms: 2,5-DIBROMO-3-FLUOROPYRIDINE
• CAS NO: 156772-60-0
• Molecular Formula: C₅H₂Br₂FN
• Molecular Weight: 254.88
• Product Categories: Pyridine;Halides;Heterocycles;Pyridines;Boronic Acid;pyridine series
• Mol File: 156772-60-0.mol

Chemical Properties

• Boiling Point: 215.9 °C at 760 mmHg
• Flash Point: 84.4 °C
• Appearance: White/Solid
• Density: 2.137 g/cm³
• Vapor Pressure: 0.212mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -3.99±0.20(Predicted)
• CAS DataBase Reference: 2,5-DIBROMO-3-FLUOROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIBROMO-3-FLUOROPYRIDINE(156772-60-0)
• EPA Substance Registry System: 2,5-DIBROMO-3-FLUOROPYRIDINE(156772-60-0)

Safety Data

• RIDADR: UN2811
• HazardClass: 6.1
• Hazardous Substances Data: 156772-60-0(Hazardous Substances Data)

Usage

Uses

2,5-Dibromo-3-fluoropyridine can be used as PRC2 inhibitors to treat cancer.

InChI:InChI=1/C5H2Br2FN/c6-3-1-4(8)5(7)9-2-3/h1-2H

Upstream product

• 90902-84-4 2,5-dibromopyridin-3-ylamine 

Downstream Products

• 156772-62-2 5-bromo-3-fluoro-2-(4-octyloxyphenyl)pyridine 
• 1162674-74-9 5-bromo-3-fluoro-2-methylpyridine 
• 1160936-52-6 1-(5-bromo-3-fluoropyridin-2-yl)ethan-1-one 

Relevant articles and documents

Application of 1,1-ADEQUATE, HMBC, and Density Functional Theory to Determine Regioselectivity in the Halogenation of Pyridine N-Oxides

The 1,1-ADEQUATE spectrum clearly shows specific two-bond proton to carbon correlations to unequivocally distinguish the major and minor regioisomers of ortho-halogenated pyridines and to aid in assignment of the corresponding proton and carbon chemical shifts. M06-2X/6-31+G(d,p) free energies of the regioisomeric intermediates arising from deprotonation correctly predict the experimentally observed preference and thus can be used to tune the substituent pattern to yield a desired regiochemical outcome.

Highly Regioselective Halogenation of Pyridine N -Oxide: Practical Access to 2-Halo-Substituted Pyridines

A highly efficient and regioselective halogenation reaction of unsymmetrical pyridine N-oxide under mild conditions is described. The methodology provides a practical access to various 2-halo-substituted pyridines, which are pharmaceutically important intermediates.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and radicals A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one alkyne according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to individual alkyne compounds with an antagonistic action against the MCH-receptor. Said compounds are suitable for producing medicaments for the treatment of metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

NOVEL ALKYNE COMPOUNDS EXHIBITING AN MCH ANTAGONISTIC EFFECT AND DRUGS CONTAINING SAID COMPOUNDS

The invention relates to an alkyne compound of general formula (I) in which A, B, W, X, Y, Z, R and R groups and residuals have the meanings given in claim 1. Drugs containing at least one type of inventive alkyne are also disclosed. The inventive drugs exhibiting an MCH-receptor antagonistic activity are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which the groups and radicals A, B, W, X, Y, Z, R1 and R2 are defined as cited in claim 1. The invention also relates to medicaments containing at least one inventive alkyne. As a result of the antagonistic action against the MCH-receptor, the inventive medicaments are suitable for treating metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), wherein the groups and radicals A, B, W, X, Y, Z, R1, and R2 have the meanings indicated in claim 1. The invention further relates to medicaments containing at least one inventive alkyne. The disclosed medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, particularly adiposity and diabetes, as a result of the MCH receptor antagonistic activity thereof.